Reply to 'Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2V617F mutation' by Dr Ronald S Go [6]

Leukemia

Volumn 21, Issue 9, 2007, Pages 2052-

  Inami, M ^a   Inokuchi, K ^a   Yamaguchi, H ^a   Dan, K ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN;

BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DISEASE COURSE; ERYTHROCYTOSIS; EXON; FUSION GENE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; LETTER; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS;

EID: 34548138920     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404826     Document Type: Letter

References (11)

1. Go RS. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2V617F mutation. Leukemia 2007, in press.
2. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-2921.
3. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005; 128: 734-736.
4. Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E. Chronic myeloid leukemia of thrombocythemic onset: A CML subtype with distinct hematological and molecular features? Leukemia 1996; 10: 1241-1243.
5. Emilia G, Marasca R, Zucchini P, Temperani P, Luppi M, Torelli G et al. BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood 2001; 97: 2187-2189.
6. Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B, Ridell B et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: Natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004; 83: 504-512.
7. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21: 1103-1104.
8. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007; 109: 4106-4107.
9. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
10. Kronenwett R, Graf T, Neumann F, Pechtel S, Steidl U, Diaz-Blanco E et al. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis. Leuk Res 2006; 30: 1323-1324.
11. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A et al. A BCR-JAK2 fusion gene as the result of a t(9;22 (p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44: 329-333.